Evidence map›Paper›PMID 33074087›Full record

ArticleMicrobial genomics2020

Azithromycin resistance mutations in

Hélène Gingras, Kévin Patron, Philippe Leprohon, Marc Ouellette

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbial genomics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Hélène GingrasAxe des Maladies Infectieuses et Immunitaires du Centre de Recherche du CHU de Québec and Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Québec, Canada.
Kévin PatronAxe des Maladies Infectieuses et Immunitaires du Centre de Recherche du CHU de Québec and Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Québec, Canada.
Philippe LeprohonAxe des Maladies Infectieuses et Immunitaires du Centre de Recherche du CHU de Québec and Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Québec, Canada.
Marc OuelletteAxe des Maladies Infectieuses et Immunitaires du Centre de Recherche du CHU de Québec and Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Québec, Canada.
Université Laval · CA

Funding

CIHR
6 · The paper itself

Abstract

We report on the combination of chemical mutagenesis, azithromycin selection and next-generation sequencing (Mut-Seq) for the identification of small nucleotide variants that decrease the susceptibility of

Indexed as

Anti-Bacterial AgentsAzithromycinDrug Resistance, BacterialEndoribonucleasesGlutamate-Ammonia LigaseHigh-Throughput Nucleotide SequencingMicrobial Sensitivity TestsMutagenesisProtein Synthesis InhibitorsRNA, Ribosomal, 23SStreptococcus pneumoniaeAnti-Bacterial AgentsAzithromycinEndoribonucleasesGlutamate-Ammonia LigaseProtein Synthesis InhibitorsRNA, Ribosomal, 23SAzithromycinchemical mutagenesisGlutaminemacrolidenext generation sequencingResistanceStreptococcus pneumoniae

Identifiers

PMID33074087
PMCPMC7725334
OpenAlexW3092687430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.